## UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD


NALOX-1 PHARMACEUTICALS, LLC, Petitioner,

v.

OPIANT PHARMACEUTICALS, INC., Patent Owner.

> Case IPR2019-00685 U.S. Patent 9,211,253

PATENT OWNER'S OBJECTIONS TO EVIDENCE



Pursuant to 37 C.F.R. § 42.64, Patent Owner Opiant Pharmaceuticals, Inc. submits the following objections to the exhibits filed by Nalox-1 Pharmaceuticals, LLC on February 19, 2019.

Patent Owner objects to **Exhibit 1004** under Federal Rules of Evidence ("FRE") 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1005** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1006** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1012** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1017** under FRE 401, 402, 403, and 901 as irrelevant and not authenticated.

Patent Owner objects to **Exhibit 1018** under FRE 401, 402, 403, 801, 802,

805, and 901 as irrelevant and inadmissible hearsay and not authenticated.

Patent Owner objects to **Exhibit 1024** under FRE 106, 401, 402, and 403 as irrelevant and incomplete.

Patent Owner objects to **Exhibit 1025** under FRE 106, 401, 402, 403, and 901 as irrelevant, incomplete, and not authenticated.

Patent Owner objects to **Exhibit 1039** FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1043** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1044** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1045** under FRE 106, 401, 402, and 403 as irrelevant and incomplete.

Patent Owner objects to **Exhibit 1050** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1051** under FRE 106, 401, 402, and 403 as incomplete.

Patent Owner objects to **Exhibit 1065** under FRE 106, 401, 402, and 403 as incomplete and an improper compilation of multiple documents.

Date: September 11, 2019

DOCKE.

Respectfully submitted,

/Jessica Tyrus Mackay/

Robert F. Green (Reg. No. 27,555) Jessica Tyrus Mackay (Reg. No. 64,742) GREEN, GRIFFITH & BORG-BREEN, LLP 676 North Michigan Avenue Suite 3900 Chicago, IL 60611 (313) 883-8000 jmackay@greengriffith.com

Counsel for Patent Owner Opiant Pharmaceuticals, Inc.

## **CERTIFICATE OF SERVICE**

Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true

and correct copy of the foregoing was served on September 11, 2019, by delivering

a copy via electronic mail on the following attorneys of record:

Yelee Y. Kim Janine A. Carlan Richard Berman Bradford Frese Christopher Yaen ARENT FOX LLP 1717 K Street NW Washington, DC 20036 Yelee.Kim@arentfox.com Janine.Carlan@arentfox.com Richard.Berman@arentfox.com Bradford.Frese@arentfox.com

> /Jessica Tyrus Mackay/ Jessica Tyrus Mackay (Reg. No. 64,742)

DOCKET